Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TNC expression may therefore play a future role in objective tumor grading and novel therapeutic approaches to this malignancy.
|
11721178 |
2001 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TNC expression was demonstrated in pancreatic stellate cells, where it could be induced by tumour necrosis factor alpha (TNFalpha), transforming growth factor beta1 (TGF-beta1) and by cancer cell supernatants supplemented with TGF-beta1.
|
16450333 |
2006 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tenascin-C (TNC) expression is known to correlate with malignancy in glioblastoma (GBM), a highly invasive and aggressive brain tumor that shows limited response to conventional therapies.
|
19147558 |
2009 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tenascin-C (TNC) is a key molecule in tissue remodeling, and high levels are observed in many diseases, including heart failure, thrombosis, atherosclerosis, and cancer.
|
24696262 |
2014 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TNC expressed in cancer tissues dominantly contains large splice variants.
|
25793576 |
2015 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tenascin-C is also expressed de novo during wound healing or in pathological conditions, including chronic inflammation and cancer.
|
27875272 |
2016 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer.
|
28341124 |
2017 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tenascin-C is a large extracellular glycoprotein not expressed under physiological conditions, but overexpressed in cancer.
|
29515769 |
2018 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Tenascin-C (TNC), an extracellular matrix glycoprotein, has been implicated in progression of various types of cancer.
|
30633201 |
2019 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tenascin C (Tnc) is an extracellular matrix glycoprotein, expressed in the CNS during development, as well as in the setting of inflammation, fibrosis and cancer, which operates as an activator of Toll-like receptor 4 (TLR4).
|
31271872 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Tenascin and other adhesion-modulating proteins in cancer.
|
7504958 |
1993 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TN-C mRNA-positive cells were often observed in localized areas, such as in cancer stroma associated with invading edges and/or in host tissues surrounding the invading cancer front, but rarely in the center of the tumors.
|
9334802 |
1997 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, targeting of crosstalk between stromal TNC and cancer cell ANXA2 could be a promising therapeutic strategy to overcome refractory pancreatic cancer.
|
31463696 |
2020 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer cell-derived TNC promotes cancer invasiveness via EMT regulation, and not cancer tissue TNC but cancer cell-specific TNC is a novel indicator of poor prognosis.
|
23645740 |
2013 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our findings identified TNC as a pivotal initiator of elevated NOTCH signaling in BTIC and define the establishment of a TN-α2β1-JAG1-NOTCH signaling axis as a candidate therapeutic target in glioma patients.<i>Cancer Res; 77(12); 3231-43.©2017 AACR</i>.
|
28416488 |
2017 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Combined analysis of tenascin-C expression and the nodule size improved the prediction of malignancy in this patient cohort.
|
22588153 |
2012 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistently, tenascin-C expression in vivo was found to correlate with fibrin deposition in several diseases associated with tenascin-C overexpression such as fibrosis, asthma and cancer.
|
21354146 |
2011 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Due to its role in remodeling processes, TN-C is involved with many pathologic states including cardiac and vascular diseases as well as inflammation and cancer.
|
22687648 |
2012 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer.
|
1711919 |
1990 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, our in vivo data derived from astrocytoma tissue arrays link increased tenascin-C and Id2 expression with high malignancy.
|
15492259 |
2004 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Given that BVI have prognostic significance for many tumor types, such as shorter cancer patient survival, increased metastasis, vessel occlusion, and organ failure, our data revealing a novel mechanism by which stromal tenascin-C promotes metastasis in human cancer, may have potential for diagnosis and therapy.
|
31288084 |
2019 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we report that Twist1, a key regulator of cancer-associated fibroblasts, directly upregulates Prrx1, which, in turn, increases the expression of Tenascin-C (TNC).
|
30069061 |
2018 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we show that engineered variants of the F16 antibody, specific to a splice isoform of tenascin-C, selectively localize to the subendothelial tumor extracellular matrix in three mouse models of human cancer (U87, A431, MDA-MB-231).
|
27943268 |
2017 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, Oct4 transactivated TNC independent of Sp1 and resulted in cancer metastasis.
|
25609695 |
2015 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we examined the expression of Tn-C and Fibronectin in human cancer-cell lines and in liver tissue of mice treated with ASD-PM to investigate the inflammatory and cell-damage effects of ASD-PM.
|
31474744 |
2019 |